E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
prevention of invasive mould disease |
|
E.1.1.1 | Medical condition in easily understood language |
Infection of the lungs by fungi |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Respiratory Tract Diseases [C08] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 20.0 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10003488 |
E.1.2 | Term | Aspergillosis |
E.1.2 | System Organ Class | 100000004862 |
|
E.1.3 | Condition being studied is a rare disease | Yes |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To investigate whether prophylaxis with ITZ DPI can reduce the incidence rate of IMD in patients with acute leukaemia undergoing remission induction chemotherapy |
|
E.2.2 | Secondary objectives of the trial |
-To investigate the safety and tolerability of ITZ DPI in patients with acute leukaemia undergoing remission-induction chemotherapy -To evaluate the PK of ITZ DPI in patients with acute leukaemia undergoing remission induction chemotherapy
|
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
1.Male or female patients ≥12 years of age 2.Patients with new or relapsed ALL or AML who cannot receive posaconazole for any reason and who are to undergo remissioninduction chemotherapy 3.Current neutropaenia resulting from the diagnosis of new or relapsed acute leukaemia or patients with expected neutropaenia for at least 10 days (an absolute neutrophil count <500 cell/mm3 or 0.5 x 109 cell/L) following remission-induction chemotherapy 4.Able to have all Screening tests performed quickly to ensure results can be obtained and evaluated before randomisation, so that the first dose of study drug for the prevention of IMD can be administered as soon as possible within 5 days of the start of remission induction chemotherapy. In ALL patients, as soon as possible within 5 days of the start of remission-induction chemotherapy means as soon as possible within 5 days of the start of high dose steroid therapy. 5.Able to comply with all study procedures, including the use of inhalers 6.If patient is a female of childbearing potential (FOCP), patient must agree to abstain from sexual intercourse or to use an effective means of birth control (oral contraceptives, intrauterine device [IUD], condoms and spermicides, vaginal ring, hormonal patch, implants), as determined by the Investigator from the first dose of study drug until 100 days following the last dose of study drug. A female patient is considered to be of childbearing potential if she has reached menarche and a) has not undergone a hysterectomy (the surgical removal of the uterus) or bilateral oophorectomy (the surgical removal of both ovaries), or b) has not been postmenopausal for 12 consecutive months (i.e., has had menses at any time during the preceding 12 months). Female patients of childbearing potential must also provide a negative blood pregnancy test at the Screening Visit. Male patients must be vasectomised, abstain from sexual intercourse, or agree to use barrier contraception (condom with spermicide), and also agree not to donate sperm from the first dose of study drug until 100 days following the last dose of study drug. 7.Patients (and/or the patient's parents or legally authorised representatives) must give written informed consent to participate in the study by signing and dating the Informed Consent Form (ICF)/Adolescent Assent Form (to be obtained prior to initiation of any study procedure) |
|
E.4 | Principal exclusion criteria |
1.Proven, probable, or possible IMD (according to 2019 European Organisation for Research and Treatment of Cancer/Mycoses Study Group Education and Research Consortium [EORTC/MSGMSGERC] criteria at Screening or in the patient's medical history 2.Pulmonary complications or active infiltrates associated with an ongoing pulmonary disease assessed by a chest CT 3.Patients with ventricular dysfunction defined as ejection fraction <55% at Screening 4.Concomitant or previous treatment with a mould-active antifungal drug within 30 days, unless the plasma level is below the limit of detection or ≥5 half-lives of the antifungal has elapsed since the treatment was given. 5.Participating in another clinical trial with exposure to any investigational drug within 30 days prior to Screening, with the exception of the current anti-leukemic treatment 6.Pregnant or nursing females 7.Any severe co-morbidity other than underlying haematological disease that may interfere with study procedures or affect the patient's safety 8.Grade 3 laspartate aminotransferase (ASAT >5 × upper limit of normal (ULN), alanine aminotransferase (ALAT >5 × ULN, or total bilirubin >3 × ULN. 9.Any contraindication or hypersensitivity to the use of fluconazole or ITZ or the excipient (mannitol) in the study drug and placebo formulations 10.Co-administration of astemizole, atorvastatin, bepridil, cisapride, dihydroergotamine, dofetilide, eletriptan, ergometrine (erginovine), ergotamine, erythromycin, levacetylmethadol (levomethadyl), lovastatin, methylergometrine (methylergonovine), midazolam, mizolastine, nisoldipine, pimozide, quinidine, sertindole, simvastatin, terfenadine and triazolam. 11.Abnormal QT interval corrected by Fridericia (QTcF): males >450 ms and females >470 ms |
|
E.5 End points |
E.5.1 | Primary end point(s) |
The primary efficacy endpoint is the: •Proportion of patients with proven or probable IMD at EOT. Diagnoses of proven or probable IMD will be evaluated according to 2019 EORTC/MSGERC criteria, as assessed by the Independent Data Review Board (IDRB) that will be blinded to treatment assignment. |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
|
E.5.2 | Secondary end point(s) |
The secondary efficacy endpoints are: •Treatment success at EOT (success defined as patients who completed treatment without developing a proven, probable, or possible IMD, without requiring systemic mould-active antifungal treatment, without discontinuation from the study due to an adverse event [AE], and who are alive). •The proportion of patients: o with proven, probable, or possible IMD at EOT and EOS o who had neutropaenia ≥10 days and with proven, probable, or possible IMD at EOT and EOS o with radiographic pulmonary infiltrates according to the central image reader at EOT and EOS o with bronchopulmonary aspergillosis at EOT and EOS o with fungal sinusitis at EOT and EOS o with proven or probable or possible IA at EOT and at EOS o with candidemia/candidiasis at EOT and EOS o requiring systemic mould-active antifungal treatment at EOT and EOS to treat a breakthrough fungal disease o alive at EOT and EOS o who died at EOT and EOS due to IMD or IA o in complete remission of their underlying malignancy at EOT and EOS •The proportion of pathogenic moulds causing proven and probable IMDs at EOT and EOS •Time to: o diagnosis of proven, probable, or possible IMD o diagnosis of IA o the onset of systemic mould-active antifungal treatment for a breakthrough fungal disease o death of any cause |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
End of treatment and end of study |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | Yes |
E.6.3 | Therapy | No |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | Yes |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | Yes |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 4 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 44 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
Belgium |
Bulgaria |
Greece |
Italy |
Poland |
Romania |
Russian Federation |
Serbia |
Spain |
Ukraine |
|
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 2 |
E.8.9.1 | In the Member State concerned months | 6 |
E.8.9.1 | In the Member State concerned days | 0 |
E.8.9.2 | In all countries concerned by the trial years | 2 |
E.8.9.2 | In all countries concerned by the trial months | 6 |
E.8.9.2 | In all countries concerned by the trial days | 0 |